Navigation Links
Researchers engineer a hybrid 5 times more effective in delivering genetic material into cells
Date:12/16/2013

Brooklyn, New York Researchers at the Polytechnic Institute of New York University (NYU-Poly) and the NYU College of Dentistry (NYUCD) have developed a carrier in their lab that is five times more efficient in delivering DNA into cells than today's commercial delivery methodsreagent vectors. This novel complex is a peptide-polymer hybrid, assembled from two separate, less effective vectors that are used to carry DNA into cells.

Results of their study, "Long Term Efficient Gene Delivery Using Polyethylenimine with Modified Tat Peptide," were published in Biomaterials. The findings were the result of a collaborative research project conducted by Dr. Seiichi Yamano at NYUCD and Dr. Jin Montclare at NYU-Poly. The outcome of the study could help researchers better understand gene function and ultimately improve gene therapy.

Non-viral vectors such as those engineered in this study are used for transfectionthe process of introducing foreign genetic material (in this case, DNA called a plasmid) into a cell. The vectors are essentially vehicles that carry the genetic matter into the cell. But transfection is not as easy. Cells are set up to keep things out of the nucleus. Even if the transported plasmid manages to permeate the cellular membrane, the cytoplasm within the cell has safeguards to stop anything from getting into the nucleus.

Traditionally, scientists have engineered viruses to carry out transfection, but viruses are problematic because cells recognize them as foreign and trigger the immune response. Virus transfection is extremely costly and presents numerous difficulties for mass processing. On the other hand, non-viral vectors do not trigger the immune system and are easily manufactured and modified for safe, more effective delivery. Their shortcoming is that they generally are effective only for short periods in transfection, as well as other forms of gene expression.

For this project, Yamano and Montclare paired a modified version of CPP HIV-1 (mTat) with PEI a non-viral vector particularly effective for delivering oligonucleotides. In combining mTat and PEI, they built a new non-viral vector, more effective than mTat or PEI individually. They tested their reagent vector both in vitrogrown in a Petri dishas well as for approximately seven months in a living organism--in vivo.

The vector may be used in the future for targeted gene therapy.


'/>"/>

Contact: Kathleen Hamilton
kathleen.hamilton@nyu.edu
718-260-3792
Polytechnic Institute of New York University
Source:Eurekalert

Related biology news :

1. New organization brings together top researchers to sequence genomes of invertebrates
2. Bonefish spawning behavior in the Bahamas surprises researchers, should aid conservation
3. Where water is limited, researchers determine how much water is enough
4. Researchers at Penn help develop a dynamic model of tissue failure
5. Leibniz Prizes 2014: DFG honors 11 outstanding researchers
6. Researchers named to National Academy of Inventors
7. Researchers at Penn show optimal framework for heartbeats
8. University researchers observe surprising bonefish spawning behavior in the Bahamas
9. ASU researchers discover chameleons use colorful language to communicate
10. Canadian researchers lead groundbreaking discovery in deadly childhood cancer
11. Mount Sinai researchers say new strain of bird flu packs a punch even after becoming drug-resistant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2020)... ... July 01, 2020 , ... ... 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host ... by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, ...
(Date:7/1/2020)... ... July 01, 2020 , ... Cure Glioblastoma, ... glioblastoma—the most common and aggressive adult brain cancer—announced today the appointments of its ... are charged with supporting the organization’s initiatives and overall vision. , "Senior Fellows ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions ... data services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: ... hospitalized patients with severe COVID-19. This is the first study of an XPO1 ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... ... 2020 , ... MedShift , a leading medical technology ... obstacles created as a result of COVID-19. As a provider at the forefront ... and medical manufacturers by expanding access to device offerings, technology services, and marketing ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... launch of a new clinical diagnostics immuno-oncology service, TissueInsight . TissueInsight ... , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists ...
(Date:6/28/2020)... ... 25, 2020 , ... With the COVID-19 pandemic impacting millions ... In an effort to better understand the cellular responses to COVID-19, the digital ... portraying therapeutic compound effects from over 1,600 approved and referenced molecules on SARS-CoV-2-infected ...
(Date:6/28/2020)... ... June 26, 2020 , ... The Security Industry ... its strong opposition to the recently introduced bicameral Facial Recognition and Biometric ... most federal use of nearly all biometric and related image analytics technologies, incorrectly ...
Breaking Biology Technology: